Delve into a biopharma giant's strategy, Eli Lilly. This past year, the company secured regulatory milestones and strategic deals. The post Eli Lilly’s strategy in motion: Beyond diabetes and obesity appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is ...| Labiotech.eu
It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting impressive results following a large, robust 72-week trial that saw obese participants lose an average of 27.3 lb, or 12.4% of their body weight with the once-daily pill.| New Atlas
This post was delivered as a Medicine in Crisis lecture at a Pills and Skills for Depression meeting that David Antonuccio organized in Reno Nevada on October 4. Kim Witczak who features throughout the post was a panellist at the meeting. I was in Houston for the Bicentenary – 49 years ago. A few […] The post Health, Care and Science in Real Life first appeared on Dr. David Healy.| Dr. David Healy
Eli Lilly (NYSE:LLY) announced today that it plans to build a new $6.5 billion manufacturing facility at Generation Park in Houston, Texas. The planned next-generation synthetic medicine active pharmaceutical product (API) facility marks the second of four new sites Lilly plans to announce this year. It follows the announcement of a $5 billion manufacturing facility… The post Lilly to build new $6.5B API manufacturing plant in Texas appeared first on Pharmaceutical Processing World.| Pharmaceutical Processing World
Eli Lilly (NYSE:LLY) announced today that it plans to build a $5 billion manufacturing facility in Goochland County, Virginia.| Pharmaceutical Processing World
Novo Nordisk, the manufacturer of Ozempic, announced a plan to reduce its global workforce by approximately 9,000 positions today. Around 5,000 positions are expected to be cut in Denmark. This will reduce the company’s workforce from its current 78,400 positions to approximately 69,400. The company’s stock has fallen about 58% over the past year as… The post Novo Nordisk to cut 9,000 jobs globally to compete in GLP-1 market appeared first on Drug Discovery and Development.| Drug Discovery and Development
Both companies have been desperate to innovate beyond their current injectable GLP-1 weight-loss drugs for a while now. The post Eli Lilly Upstages Novo Nordisk in Obesity Pill Face-Off appeared first on The Daily Upside.| The Daily Upside
Serena Williams shares her experience using GLP-1 medications for weight loss, sparking a conversation about health, stigma, and access to care.| DefenderNetwork.com
Eli Lilly and Co. has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion, in a move that bolsters Lilly's push into gene editing for cardiovascular conditions and signals renewed confidence in the sector.| Drug Discovery and Development
A recording of the full FDA Panel on SSRIs and Pregnancy is linked to the last post here. There has been extensive media coverage of this event – and 18 takes on what reporters heard can be found linked to Unsafe Safety Systems on RxISK. Roger McFillin was on thin ice, at the recent FDA […] The post There’s Something About Pregnant Mary first appeared on Dr. David Healy.| Dr. David Healy
Eli Lilly's investment in capital expansion across therapeutic areas in the U.S. now totals more than $50 billion since 2020.| Pharmaceutical Processing World
Purdue University, Eli Lilly and Merck have launched the Young Institute Pharmaceutical Manufacturing Consortium.| Pharmaceutical Processing World
What is Ozempic or Mounjaro? Weight Loss Medication is available for Type 2 Diabetes, Obesity, or high BMI with other co-morbid indications.| The Kellie Kitchen